Released Aug 14, 2024, before the open
10-Q filed Aug 14, 2024, 45 days after period end · 0001558370-24-012134
Q2 2024 · 10-Q
Revenue$13.47M$13.47M −61.6% vs Q2 2023+259.5% vs Q1 2024
Net Income-$2.20M-$2.20M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.03-$0.03 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$2,427,000N/M
Operating Cash Flowderived-$3,610,000N/M
Free Cash Flowderived-$3,782,000N/M
Margins · derived
Operating margin-18.0%−76.2 pt vs Q2 2023
Net margin-16.4%−71.5 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $13.47M | $35.08M | $8.75M | $6.43M |
| Net Income | -$2.20M | $19.34M | -$5.33M | -$11.24M |
| EPS Diluted | -$0.03 | $0.21 | -$0.11 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR